| Year |
Citation |
Score |
| 2023 |
Vlodavsky I, Kayal Y, Hilwi M, Soboh S, Sanderson RD, Ilan N. Heparanase-A single protein with multiple enzymatic and nonenzymatic functions. Proteoglycan Research. 1: e6. PMID 37547889 DOI: 10.1002/pgr2.6 |
0.408 |
|
| 2023 |
Tripathi K, Bandari SK, Sanderson RD. Extracellular vesicles released during hypoxia transport heparanase and enhance macrophage migration, endothelial tube formation and cancer cell stemness. Proteoglycan Research. 1. PMID 37091070 DOI: 10.1002/pgr2.1 |
0.388 |
|
| 2020 |
Amin R, Tripathi K, Sanderson RD. Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function. Cells. 9. PMID 32899927 DOI: 10.3390/Cells9092038 |
0.436 |
|
| 2020 |
Bandari SK, Tripathi K, Rangarajan S, Sanderson RD. Therapy-induced chemoexosomes: Sinister small extracellular vesicles that support tumor survival and progression. Cancer Letters. PMID 32858103 DOI: 10.1016/J.Canlet.2020.08.022 |
0.421 |
|
| 2020 |
Rangarajan S, Richter JR, Richter RP, Bandari SK, Tripathi K, Vlodavsky I, Sanderson RD. Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 22155420937087. PMID 32623935 DOI: 10.1369/0022155420937087 |
0.407 |
|
| 2020 |
Zhang GL, Gutter-Kapon L, Ilan N, Batool T, Singh K, Digre A, Luo Z, Sandler S, Shaked Y, Sanderson RD, Wang XM, Li JP, Vlodavsky I. Significance of host heparanase in promoting tumor growth and metastasis. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 32534153 DOI: 10.1016/J.Matbio.2020.06.001 |
0.389 |
|
| 2020 |
Purushothaman A, Sanderson RD. Heparanase: A Dynamic Promoter of Myeloma Progression. Advances in Experimental Medicine and Biology. 1221: 331-349. PMID 32274716 DOI: 10.1007/978-3-030-34521-1_12 |
0.413 |
|
| 2020 |
Rangarajan S, Tripathi K, Bandari SK, Brown EE, Sanderson RD. Heparanase in myeloma related renal dysfunction: Role in promoting nephrotoxicity and potential as a novel biomarker for early detection. Journal of Clinical Oncology. 38: e20554-e20554. DOI: 10.1200/Jco.2020.38.15_Suppl.E20554 |
0.354 |
|
| 2019 |
Tripathi K, Ramani VC, Bandari SK, Amin R, Brown EE, Ritchie JP, Stewart MD, Sanderson RD. Heparanase promotes myeloma stemness and in vivo tumorigenesis. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 31812535 DOI: 10.1016/J.Matbio.2019.11.004 |
0.431 |
|
| 2019 |
Bhattacharya U, Gutter-Kapon L, Kan T, Boyango I, Barash U, Yang SM, Liu J, Gross-Cohen M, Sanderson RD, Shaked Y, Ilan N, Vlodavsky I. Heparanase and chemotherapy synergize to drive macrophage activation and enhance tumor growth. Cancer Research. PMID 31690669 DOI: 10.1158/0008-5472.Can-19-1676 |
0.407 |
|
| 2018 |
Chanda D, Otoupalova E, Hough KP, Locy ML, Bernard K, Deshane JS, Sanderson RD, Mobley JA, Thannickal VJ. Fibronectin on the Surface of Extracellular Vesicles Mediates Fibroblast Invasion. American Journal of Respiratory Cell and Molecular Biology. PMID 30321056 DOI: 10.1165/Rcmb.2018-0062Oc |
0.327 |
|
| 2018 |
Karamanos NK, Piperigkou Z, Theocharis AD, Watanabe H, Franchi M, Baud S, Brézillon S, Götte M, Passi A, Vigetti D, Ricard-Blum S, Sanderson RD, Neill T, Iozzo RV. Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics. Chemical Reviews. PMID 30204432 DOI: 10.1021/Acs.Chemrev.8B00354 |
0.34 |
|
| 2018 |
Galli M, Chatterjee M, Grasso M, Specchia G, Magen H, Einsele H, Celeghini I, Barbieri P, Paoletti D, Pace S, Sanderson RD, Rambaldi A, Nagler A. Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy. Haematologica. PMID 29700168 DOI: 10.3324/Haematol.2017.182865 |
0.329 |
|
| 2017 |
Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD, Ponnazhagan S. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Advances. 1: 2375-2385. PMID 29296887 DOI: 10.1182/Bloodadvances.2017007310 |
0.411 |
|
| 2017 |
Vlodavsky I, Gross-Cohen M, Weissmann M, Ilan N, Sanderson RD. Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression. Trends in Biochemical Sciences. PMID 29162390 DOI: 10.1016/J.Tibs.2017.10.007 |
0.437 |
|
| 2017 |
Sanderson RD, Bandari SK, Vlodavsky I. Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 29106944 DOI: 10.1016/J.Matbio.2017.10.007 |
0.383 |
|
| 2017 |
Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, Mobley JA, Zhang Y, Brown EE, Vlodavsky I, Sanderson RD. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 28888912 DOI: 10.1016/J.Matbio.2017.09.001 |
0.495 |
|
| 2016 |
Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N. Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 29: 54-75. PMID 27912844 DOI: 10.1016/J.Drup.2016.10.001 |
0.464 |
|
| 2016 |
Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: New mechanisms and targets for therapy. The Febs Journal. PMID 27758044 DOI: 10.1111/Febs.13932 |
0.391 |
|
| 2016 |
Couchman JR, Multhaupt H, Sanderson RD. Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer. F1000research. 5. PMID 27408707 DOI: 10.12688/F1000Research.8543.1 |
0.446 |
|
| 2016 |
Beauvais DM, Jung O, Yang Y, Sanderson RD, Rapraeger AC. Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth. Cancer Research. PMID 27364558 DOI: 10.1158/0008-5472.Can-16-0232 |
0.407 |
|
| 2016 |
Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A, Sanderson RD. Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 27016342 DOI: 10.1016/J.Matbio.2016.03.006 |
0.449 |
|
| 2016 |
Jung O, Trapp-Stamborski V, Purushothaman A, Jin H, Wang H, Sanderson RD, Rapraeger AC. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis. 5: e202. PMID 26926788 DOI: 10.1038/oncsis.2016.5 |
0.386 |
|
| 2016 |
Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N. Heparanase: From basic research to therapeutic applications in cancer and inflammation Drug Resistance Updates. 29: 54-75. DOI: 10.1016/j.drup.2016.10.001 |
0.365 |
|
| 2015 |
Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. PMID 26624982 DOI: 10.18632/Oncotarget.6408 |
0.382 |
|
| 2015 |
Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE, Sanderson RD. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. The Journal of Biological Chemistry. PMID 26601950 DOI: 10.1074/Jbc.M115.686295 |
0.499 |
|
| 2015 |
Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, Gopal S, Gomes A, Afratis N, Lim HC, Couchman JR, Filmus J, Sanderson RD, Schaefer L, Iozzo RV, et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochimica Et Biophysica Acta. 1855: 276-300. PMID 25829250 DOI: 10.1016/J.Bbcan.2015.03.006 |
0.372 |
|
| 2015 |
Stewart MD, Ramani VC, Sanderson RD. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: A novel mechanism of tumor-host cross-talk Journal of Biological Chemistry. 290: 941-949. PMID 25404732 DOI: 10.1074/Jbc.M114.608455 |
0.44 |
|
| 2015 |
Galli M, Magen H, Einsele H, Chatterjee M, Grasso M, Specchia G, Barbieri P, Paoletti D, Pace S, Sanderson RD, Rambaldi A, Nagler A. Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study Blood. 126: 3246-3246. DOI: 10.1182/Blood.V126.23.3246.3246 |
0.378 |
|
| 2014 |
Stewart MD, Sanderson RD. Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biology : Journal of the International Society For Matrix Biology. 35: 56-9. PMID 24309018 DOI: 10.1016/J.Matbio.2013.10.009 |
0.386 |
|
| 2014 |
Ramani VC, Sanderson RD. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biology : Journal of the International Society For Matrix Biology. 35: 215-22. PMID 24145151 DOI: 10.1016/J.Matbio.2013.10.005 |
0.435 |
|
| 2014 |
Ramani VPC, Zhan F, Tricot G, Sanderson RD. Abstract 1708: Heparanase regulates response to chemotherapy in myeloma Cancer Research. 74: 1708-1708. DOI: 10.1158/1538-7445.Am2014-1708 |
0.487 |
|
| 2014 |
Stewart M, Ramani V, Sanderson R. Abstract 1156: Shed syndecan-1 downregulates histone acetyltransferase activity and shuttles HGF to the nucleus of tumor and host cells Cancer Research. 74: 1156-1156. DOI: 10.1158/1538-7445.Am2014-1156 |
0.514 |
|
| 2013 |
Ruan J, Trotter TN, Nan L, Luo R, Javed A, Sanderson RD, Suva LJ, Yang Y. Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone. 57: 10-7. PMID 23895995 DOI: 10.1016/J.Bone.2013.07.024 |
0.351 |
|
| 2013 |
Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. The Journal of Biological Chemistry. 288: 10093-9. PMID 23430739 DOI: 10.1074/Jbc.C112.444562 |
0.504 |
|
| 2013 |
Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, Sanderson RD. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. The Febs Journal. 280: 2294-306. PMID 23374281 DOI: 10.1111/Febs.12168 |
0.376 |
|
| 2013 |
Purushothaman A, Sanderson RD. Abstract A17: Glycosaminoglycans regulates histone acetylation status in multiple myeloma Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-A17 |
0.359 |
|
| 2012 |
Purushothaman A, Babitz SK, Sanderson RD. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. The Journal of Biological Chemistry. 287: 41288-96. PMID 23048032 DOI: 10.1074/Jbc.M112.391417 |
0.34 |
|
| 2012 |
Sanderson RD, Iozzo RV. Targeting heparanase for cancer therapy at the tumor-matrix interface. Matrix Biology : Journal of the International Society For Matrix Biology. 31: 283-4. PMID 22655968 DOI: 10.1016/J.Matbio.2012.05.001 |
0.324 |
|
| 2012 |
Ramani VC, Pruett PS, Thompson CA, DeLucas LD, Sanderson RD. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. The Journal of Biological Chemistry. 287: 9952-61. PMID 22298773 DOI: 10.1074/Jbc.M111.330803 |
0.42 |
|
| 2012 |
Nan L, Chen H, Ruan J, Sollie RS, Schafer C, Crittenden FT, Purushothaman A, Sanderson RD, Javed A, Yang Y. Runx2 Transcription Factor Regulates Heparanase-Induced Bone Resorption in Multiple Myeloma Blood. 120: 567-567. DOI: 10.1182/Blood.V120.21.567.567 |
0.452 |
|
| 2012 |
Ramani VPC, Sanderson RD. Heparanase Regulates Response to Proteasomal Inhibition in Myeloma Blood. 120: 4902-4902. DOI: 10.1182/Blood.V120.21.4902.4902 |
0.496 |
|
| 2012 |
Schnaar R, Paulson JC, Macauley MS, Nycholat C, Pfrengle F, Rademacher C, Mahan A, Dionne K, Suscovich T, Alter G, Katoh T, Kiwamoto T, Brummet M, Bochner B, Tiemeyer M, ... ... Sanderson RD, ... ... Sanderson R, et al. Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology Glycobiology. 22: 1518-1650. DOI: 10.1093/Glycob/Cws127 |
0.345 |
|
| 2011 |
Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. The Journal of Biological Chemistry. 286: 30377-83. PMID 21757697 DOI: 10.1074/Jbc.M111.254789 |
0.475 |
|
| 2011 |
Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1382-93. PMID 21257720 DOI: 10.1158/1078-0432.Ccr-10-2476 |
0.382 |
|
| 2011 |
Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. Journal of Cellular and Molecular Medicine. 15: 1013-31. PMID 21155971 DOI: 10.1111/J.1582-4934.2010.01236.X |
0.38 |
|
| 2011 |
Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. The Journal of Biological Chemistry. 286: 6490-9. PMID 21131364 DOI: 10.1074/Jbc.M110.183277 |
0.493 |
|
| 2010 |
Yang Y, Ren Y, Ramani VC, Nan L, Suva LJ, Sanderson RD. Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Research. 70: 8329-38. PMID 20978204 DOI: 10.1158/0008-5472.Can-10-2179 |
0.448 |
|
| 2010 |
Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. The Febs Journal. 277: 3890-903. PMID 20840586 DOI: 10.1111/J.1742-4658.2010.07799.X |
0.46 |
|
| 2010 |
Kelly T, Suva LJ, Nicks KM, MacLeod V, Sanderson RD. Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 25: 1295-304. PMID 20200931 DOI: 10.1002/Jbmr.16 |
0.428 |
|
| 2010 |
Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, Sanderson RD. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood. 115: 2449-57. PMID 20097882 DOI: 10.1182/Blood-2009-07-234757 |
0.41 |
|
| 2009 |
Sanderson RD, Epstein J. Myeloma bone disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 1783-8. PMID 19839769 DOI: 10.1359/Jbmr.090901 |
0.313 |
|
| 2009 |
Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends in Biochemical Sciences. 34: 511-9. PMID 19733083 DOI: 10.1016/J.Tibs.2009.06.005 |
0.481 |
|
| 2009 |
Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K, Sanderson RD. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. The Journal of Biological Chemistry. 284: 26085-95. PMID 19596856 DOI: 10.1074/Jbc.M109.018473 |
0.477 |
|
| 2009 |
Chen L, Sanderson RD. Heparanase regulates levels of syndecan-1 in the nucleus. Plos One. 4: e4947. PMID 19305494 DOI: 10.1371/Journal.Pone.0004947 |
0.465 |
|
| 2009 |
Yang Y, Nan L, Suva LJ, Sanderson RD. Heparanase Promotes Osteolysis by Upregulating RANKL– A Novel Role for Heparanase in Multiple Myeloma. Blood. 114: 2821-2821. DOI: 10.1182/Blood.V114.22.2821.2821 |
0.496 |
|
| 2008 |
Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiology of Haemostasis and Thrombosis. 36: 195-203. PMID 19176992 DOI: 10.1159/000175157 |
0.45 |
|
| 2008 |
Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. The Journal of Biological Chemistry. 283: 32628-36. PMID 18812315 DOI: 10.1074/Jbc.M806266200 |
0.468 |
|
| 2008 |
Reigle KL, Di Lullo G, Turner KR, Last JA, Chervoneva I, Birk DE, Funderburgh JL, Elrod E, Germann MW, Surber C, Sanderson RD, San Antonio JD. Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion. Journal of Cellular Biochemistry. 104: 1684-98. PMID 18348167 DOI: 10.1002/Jcb.21735 |
0.391 |
|
| 2008 |
Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clinical & Experimental Metastasis. 25: 149-59. PMID 18027090 DOI: 10.1007/S10585-007-9125-3 |
0.428 |
|
| 2008 |
Yang Y, Ritchie JP, Suva LJ, Sanderson RD. Heparanase Promotes the Osteolytic Phenotype in Multiple Myeloma Blood. 112: 841-841. DOI: 10.1182/Blood.V112.11.841.841 |
0.411 |
|
| 2008 |
Ritchie JP, Naggi A, Torri G, Casu B, Pisano C, Carminati P, Vlodavsky I, Sanderson RD, Yang Y. Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo Blood. 112: 5165-5165. DOI: 10.1182/Blood.V112.11.5165.5165 |
0.446 |
|
| 2008 |
Yang Y, Ritchie JP, Swain T, Naggi A, Torri G, Casu B, Pisano C, Carminati P, Vlodavsky I, Sanderson RD. The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo Blood. 112: 246-246. DOI: 10.1182/Blood.V112.11.246.246 |
0.46 |
|
| 2007 |
Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD, ... ... Sanderson RD, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 110: 2041-8. PMID 17536013 DOI: 10.1182/Blood-2007-04-082495 |
0.429 |
|
| 2007 |
Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. The Journal of Biological Chemistry. 282: 13326-33. PMID 17347152 DOI: 10.1074/Jbc.M611259200 |
0.491 |
|
| 2007 |
Yang Y, Swain T, Naggi A, Torri G, Casu B, Vlodavsky I, Sanderson RD. A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment. Blood. 110: 1502-1502. DOI: 10.1182/Blood.V110.11.1502.1502 |
0.44 |
|
| 2006 |
Gökden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gökden M. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 14: 173-7. PMID 16785785 DOI: 10.1097/01.Pai.0000168592.58721.7D |
0.321 |
|
| 2006 |
Yang Y, Frith AE, Theus A, Macleod V, Sanderson RD. Expression of Soluble Syndecan-1 or Heparanase by Myeloma Cells Enhances Levels of Angiogenic Growth Factors Present in Endothelial Cells. Blood. 108: 3448-3448. DOI: 10.1182/Blood.V108.11.3448.3448 |
0.432 |
|
| 2005 |
Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. The Journal of Biological Chemistry. 280: 40066-73. PMID 16192265 DOI: 10.1074/Jbc.M508136200 |
0.433 |
|
| 2005 |
Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. Journal of Cellular Biochemistry. 96: 897-905. PMID 16149080 DOI: 10.1002/Jcb.20602 |
0.471 |
|
| 2005 |
Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Research. 65: 5778-84. PMID 15994953 DOI: 10.1158/0008-5472.Can-05-0749 |
0.475 |
|
| 2005 |
Langford JK, Yang Y, Kieber-Emmons T, Sanderson RD. Identification of an invasion regulatory domain within the core protein of syndecan-1. The Journal of Biological Chemistry. 280: 3467-73. PMID 15563454 DOI: 10.1074/Jbc.M412451200 |
0.442 |
|
| 2005 |
Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood. 105: 1303-9. PMID 15471949 DOI: 10.1182/Blood-2004-06-2141 |
0.437 |
|
| 2005 |
Yang Y, MacLeod V, Theus AM, Sanderson RD, Zhan F, Shaughnessy J. Heparanase Upregulates Synthesis and Expression of Syndecan-1 (CD138) - A Novel Growth Regulatory Loop for Myeloma Tumors. Blood. 106: 625-625. DOI: 10.1182/Blood.V106.11.625.625 |
0.52 |
|
| 2005 |
Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD. Extracellular Endosulfatases (Sulfs) Inhibit Myeloma Tumor Growth In Vivo. Blood. 106: 3386-3386. DOI: 10.1182/Blood.V106.11.3386.3386 |
0.471 |
|
| 2004 |
Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biology : Journal of the International Society For Matrix Biology. 23: 341-52. PMID 15533755 DOI: 10.1016/J.Matbio.2004.08.004 |
0.417 |
|
| 2004 |
Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD, Marchetti D. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. The Journal of Biological Chemistry. 279: 8047-55. PMID 14630925 DOI: 10.1074/Jbc.M304872200 |
0.529 |
|
| 2003 |
Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Research. 63: 8749-56. PMID 14695190 |
0.344 |
|
| 2003 |
Wilkins-Port CE, Sanderson RD, Tominna-Sebald E, McKeown-Longo PJ. Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnover. Cell Communication & Adhesion. 10: 85-103. PMID 14681059 DOI: 10.1080/Cac.10.2.85.103 |
0.366 |
|
| 2003 |
Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, Hamann J, Gordon S, Lin HH. The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood. 102: 2916-24. PMID 12829604 DOI: 10.1182/Blood-2002-11-3540 |
0.387 |
|
| 2003 |
Yang Y, Børset M, Langford JK, Sanderson RD. Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface. The Journal of Biological Chemistry. 278: 12888-93. PMID 12566461 DOI: 10.1074/Jbc.M209440200 |
0.413 |
|
| 2002 |
Bayer-Garner IB, Sanderson RD, Smoller BR. Syndecan-1 is strongly expressed in the anagen hair follicle outer root sheath and in the dermal papilla but expression diminishes with involution of the hair follicle. The American Journal of Dermatopathology. 24: 484-9. PMID 12454600 DOI: 10.1097/00000372-200212000-00005 |
0.425 |
|
| 2002 |
Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 100: 3002-7. PMID 12351414 DOI: 10.1182/Blood-2002-04-1190 |
0.369 |
|
| 2002 |
Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Research. 62: 3722-8. PMID 12097281 |
0.348 |
|
| 2002 |
Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 100: 610-7. PMID 12091355 DOI: 10.1182/Blood.V100.2.610 |
0.522 |
|
| 2002 |
Langford JK, Sanderson RD. Measurements of glycosaminoglycan-based cell interactions. Methods in Cell Biology. 69: 297-308. PMID 12071000 DOI: 10.1016/S0091-679X(02)69019-3 |
0.429 |
|
| 2002 |
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 99: 1745-57. PMID 11861292 DOI: 10.1182/Blood.V99.5.1745 |
0.334 |
|
| 2002 |
Lacy HM, Sanderson RD. 6xHis promotes binding of a recombinant protein to heparan sulfate. Biotechniques. 32: 254, 256, 258. PMID 11848397 DOI: 10.2144/02322Bm04 |
0.71 |
|
| 2002 |
Mukunyadzi P, Sanderson RD, Fan CY, Smoller BR. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 15: 45-9. PMID 11796840 DOI: 10.1038/Modpathol.3880488 |
0.403 |
|
| 2002 |
Bayer-Garner I, Dilday B, Sanderson R, Smoller B. Acantholysis and spongiosis are associated with loss of syndecan-1 expression. Journal of Cutaneous Pathology. 28: 135-9. PMID 11168765 DOI: 10.1034/J.1600-0560.2001.028003135.X |
0.382 |
|
| 2001 |
Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 14: 1052-8. PMID 11598177 DOI: 10.1038/Modpathol.3880435 |
0.44 |
|
| 2001 |
Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood. 98: 2160-5. PMID 11568003 DOI: 10.1182/Blood.V98.7.2160 |
0.758 |
|
| 2001 |
Langford JK, Sanderson RD. Regulatory roles of syndecans in cell adhesion and invasion. Methods in Molecular Biology (Clifton, N.J.). 171: 495-503. PMID 11450263 DOI: 10.1385/1-59259-209-0:495 |
0.406 |
|
| 2001 |
Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Seminars in Cell & Developmental Biology. 12: 89-98. PMID 11292374 DOI: 10.1006/Scdb.2000.0241 |
0.506 |
|
| 2000 |
Iba K, Albrechtsen R, Gilpin B, Fröhlich C, Loechel F, Zolkiewska A, Ishiguro K, Kojima T, Liu W, Langford JK, Sanderson RD, Brakebusch C, Fässler R, Wewer UM. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading Journal of Cell Biology. 149: 1143-1155. PMID 10831617 DOI: 10.1083/Jcb.149.5.1143 |
0.424 |
|
| 2000 |
Bayer-Garner IB, Dilday B, Sanderson RD, Smoller BR. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma. The American Journal of Dermatopathology. 22: 119-22. PMID 10770430 DOI: 10.1097/00000372-200004000-00005 |
0.468 |
|
| 2000 |
Kelly T, Børset M, Abe E, Gaddy-Kurten D, Sanderson RD. Matrix metalloproteinases in multiple myeloma. Leukemia & Lymphoma. 37: 273-81. PMID 10752979 DOI: 10.3109/10428190009089428 |
0.418 |
|
| 2000 |
Seidel C, Børset M, Hjertner Ø, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity Blood. 96: 3139-3146. DOI: 10.1182/Blood.V96.9.3139.H8003139_3139_3146 |
0.438 |
|
| 2000 |
Børset M, Hjertner Ø, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins Blood. 96: 2528-2536. DOI: 10.1182/Blood.V96.7.2528 |
0.451 |
|
| 2000 |
Børset M, Hjertner Ø, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins Blood. 96: 2528-2536. DOI: 10.1182/BLOOD.V96.7.2528 |
0.349 |
|
| 1999 |
Bayer-Garner IB, Sanderson RD, Smoller BR. Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma. Journal of Cutaneous Pathology. 26: 386-90. PMID 10551410 DOI: 10.1111/J.1600-0560.1999.Tb01862.X |
0.445 |
|
| 1999 |
Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma American Journal of Clinical Pathology. 112: 377-383. PMID 10478144 DOI: 10.1093/Ajcp/112.3.377 |
0.384 |
|
| 1999 |
Dhodapkar MV, Sanderson RD. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Leukemia & Lymphoma. 34: 35-43. PMID 10350330 DOI: 10.3109/10428199909083378 |
0.528 |
|
| 1999 |
Kaushal GP, Xiong X, Athota AB, Rozypal TL, Sanderson RD, Kelly T. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. British Journal of Haematology. 104: 365-73. PMID 10050721 DOI: 10.1046/J.1365-2141.1999.01180.X |
0.423 |
|
| 1998 |
Langford JK, Stanley MJ, Cao D, Sanderson RD. Multiple heparan sulfate chains are required for optimal syndecan-1 function Journal of Biological Chemistry. 273: 29965-29971. PMID 9792716 DOI: 10.1074/Jbc.273.45.29965 |
0.425 |
|
| 1998 |
Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD, Sanderson RD. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. The Journal of Biological Chemistry. 273: 22825-32. PMID 9712917 DOI: 10.1074/Jbc.273.35.22825 |
0.461 |
|
| 1998 |
Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD. Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation Blood. 91: 2679-2688. DOI: 10.1182/Blood.V91.8.2679.2679_2679_2688 |
0.452 |
|
| 1995 |
Stanley MJ, Liebersbach BF, Liu W, Anhalt DJ, Sanderson RD. Heparan sulfate-mediated cell aggregation: Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells Journal of Biological Chemistry. 270: 5077-5083. PMID 7890615 DOI: 10.1074/Jbc.270.10.5077 |
0.443 |
|
| 1995 |
Sanderson RD, Liebersbach BF. Syndecans as Anti-invasive Molecules on the Surface of Tumor Cells. Trends in Glycoscience and Glycotechnology. 7: 513-524. DOI: 10.4052/Tigg.7.513 |
0.469 |
|
| 1994 |
Sneed TB, Stanley DJ, Young LA, Sanderson RD. Interleukin-6 regulates expression of the syndecan-1 proteoglycan on B lymphoid cells. Cellular Immunology. 153: 456-67. PMID 8118875 DOI: 10.1006/Cimm.1994.1042 |
0.357 |
|
| 1994 |
San Antonio JD, Karnovsky MJ, Gay S, Sanderson RD, Lander AD. Interactions of syndecan-1 and heparin with human collagens. Glycobiology. 4: 327-32. PMID 7949658 DOI: 10.1093/Glycob/4.3.327 |
0.332 |
|
| 1993 |
Ridley R, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson R. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen Blood. 81: 767-774. DOI: 10.1182/Blood.V81.3.767.767 |
0.51 |
|
| 1993 |
Ridley R, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson R. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen Blood. 81: 767-774. DOI: 10.1182/blood.V81.3.767.767 |
0.42 |
|
| 1992 |
Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regulation. 1: 27-35. PMID 2519615 DOI: 10.1091/Mbc.1.1.27 |
0.41 |
|
| 1992 |
Lalor PA, Nossal GJ, Sanderson RD, McHeyzer-Williams MG. Functional and molecular characterization of single, (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. European Journal of Immunology. 22: 3001-11. PMID 1425924 DOI: 10.1002/Eji.1830221136 |
0.337 |
|
| 1992 |
Sanderson RD, Hinkes MT, Bernfield M. Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratify. The Journal of Investigative Dermatology. 99: 390-6. PMID 1401995 DOI: 10.1111/1523-1747.Ep12616103 |
0.423 |
|
| 1991 |
Boutin EL, Sanderson RD, Bernfield M, Cunha GR. Epithelial-mesenchymal interactions in uterus and vagina alter the expression of the cell surface proteoglycan, syndecan. Developmental Biology. 148: 63-74. PMID 1936576 DOI: 10.1016/0012-1606(91)90317-V |
0.373 |
|
| 1990 |
Bernfield M, Sanderson RD. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 327: 171-86. PMID 1969657 DOI: 10.1098/Rstb.1990.0052 |
0.467 |
|
| 1989 |
Sanderson RD, Bernfield M. Molecular polymorphism of a cell surface proteoglycan: distinct structures on simple and stratified epithelia. Proceedings of the National Academy of Sciences of the United States of America. 85: 9562-6. PMID 3144000 DOI: 10.1073/Pnas.85.24.9562 |
0.412 |
|
| 1986 |
Sanderson RD, Fitch JM, Linsenmayer TR, Mayne R. Fibroblasts promote the formation of a continuous basal lamina during myogenesis in vitro. The Journal of Cell Biology. 102: 740-7. PMID 3949876 DOI: 10.1083/Jcb.102.3.740 |
0.334 |
|
| Show low-probability matches. |